Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking

Stopped early · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Tobacco Dependence

In brief

The purpose of this study is to determine: 1) the short-term clinical efficacy and safety of bupropion for helping adolescent tobacco smokers quit, and 2) The role of withdrawal symptoms in the maintenance of smoking in adolescents.

Key facts

Study ID

NCT00248118

Run by

National Institute on Drug Abuse (NIDA)

People needed

72

Starts

2005-01-01

Expected to finish

2008-05-01

Last updated by the study team

2016-09-23

Who can join

Age: 13 and older, up to 17. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• More than 100 lbs
• IQ greater than 80
• General good health
• Not pregnant
• Non-Smoker: No cigarettes in last 6 months, less than 5 in lifetime
• Smokers: Smoke more than 6 cigarettes per day for at least 6 months

You may not qualify if…

• Cardiac, Central Nervous System (CNS) or severe psychiatric disorder
• Psychoactive medications (including nicotine replacement)
• Substance use disorder

Where it is running

• Teen Tobacco Addiction Research Clinic, NIDA Intramural Research Program — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.